Cargando…
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
The SARS-CoV-2 3CL protease (3CL(pro)) is an attractive therapeutic target, as it is essential to the virus and highly conserved among coronaviruses. However, our current understanding of its tolerance to mutations is limited. Here, we develop a yeast-based deep mutational scanning approach to syste...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365866/ https://www.ncbi.nlm.nih.gov/pubmed/36029764 http://dx.doi.org/10.1016/j.chom.2022.08.003 |
_version_ | 1784765436666052608 |
---|---|
author | Iketani, Sho Hong, Seo Jung Sheng, Jenny Bahari, Farideh Culbertson, Bruce Atanaki, Fereshteh Fallah Aditham, Arjun K. Kratz, Alexander F. Luck, Maria I. Tian, Ruxiao Goff, Stephen P. Montazeri, Hesam Sabo, Yosef Ho, David D. Chavez, Alejandro |
author_facet | Iketani, Sho Hong, Seo Jung Sheng, Jenny Bahari, Farideh Culbertson, Bruce Atanaki, Fereshteh Fallah Aditham, Arjun K. Kratz, Alexander F. Luck, Maria I. Tian, Ruxiao Goff, Stephen P. Montazeri, Hesam Sabo, Yosef Ho, David D. Chavez, Alejandro |
author_sort | Iketani, Sho |
collection | PubMed |
description | The SARS-CoV-2 3CL protease (3CL(pro)) is an attractive therapeutic target, as it is essential to the virus and highly conserved among coronaviruses. However, our current understanding of its tolerance to mutations is limited. Here, we develop a yeast-based deep mutational scanning approach to systematically profile the activity of all possible single mutants of the 3CL(pro) and validate a subset of our results within authentic viruses. We reveal that the 3CL(pro) is highly malleable and is capable of tolerating mutations throughout the protein. Yet, we also identify specific residues that appear immutable, suggesting that these may be targets for future 3CL(pro) inhibitors. Finally, we utilize our screening as a basis to identify E166V as a resistance-conferring mutation against the clinically used 3CL(pro) inhibitor, nirmatrelvir. Collectively, the functional map presented herein may serve as a guide to better understand the biological properties of the 3CL(pro) and for drug development against coronaviruses. |
format | Online Article Text |
id | pubmed-9365866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93658662022-08-11 Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites Iketani, Sho Hong, Seo Jung Sheng, Jenny Bahari, Farideh Culbertson, Bruce Atanaki, Fereshteh Fallah Aditham, Arjun K. Kratz, Alexander F. Luck, Maria I. Tian, Ruxiao Goff, Stephen P. Montazeri, Hesam Sabo, Yosef Ho, David D. Chavez, Alejandro Cell Host Microbe Brief Report The SARS-CoV-2 3CL protease (3CL(pro)) is an attractive therapeutic target, as it is essential to the virus and highly conserved among coronaviruses. However, our current understanding of its tolerance to mutations is limited. Here, we develop a yeast-based deep mutational scanning approach to systematically profile the activity of all possible single mutants of the 3CL(pro) and validate a subset of our results within authentic viruses. We reveal that the 3CL(pro) is highly malleable and is capable of tolerating mutations throughout the protein. Yet, we also identify specific residues that appear immutable, suggesting that these may be targets for future 3CL(pro) inhibitors. Finally, we utilize our screening as a basis to identify E166V as a resistance-conferring mutation against the clinically used 3CL(pro) inhibitor, nirmatrelvir. Collectively, the functional map presented herein may serve as a guide to better understand the biological properties of the 3CL(pro) and for drug development against coronaviruses. Elsevier Inc. 2022-10-12 2022-08-11 /pmc/articles/PMC9365866/ /pubmed/36029764 http://dx.doi.org/10.1016/j.chom.2022.08.003 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Brief Report Iketani, Sho Hong, Seo Jung Sheng, Jenny Bahari, Farideh Culbertson, Bruce Atanaki, Fereshteh Fallah Aditham, Arjun K. Kratz, Alexander F. Luck, Maria I. Tian, Ruxiao Goff, Stephen P. Montazeri, Hesam Sabo, Yosef Ho, David D. Chavez, Alejandro Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites |
title | Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites |
title_full | Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites |
title_fullStr | Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites |
title_full_unstemmed | Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites |
title_short | Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites |
title_sort | functional map of sars-cov-2 3cl protease reveals tolerant and immutable sites |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365866/ https://www.ncbi.nlm.nih.gov/pubmed/36029764 http://dx.doi.org/10.1016/j.chom.2022.08.003 |
work_keys_str_mv | AT iketanisho functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT hongseojung functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT shengjenny functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT baharifarideh functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT culbertsonbruce functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT atanakifereshtehfallah functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT adithamarjunk functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT kratzalexanderf functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT luckmariai functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT tianruxiao functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT goffstephenp functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT montazerihesam functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT saboyosef functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT hodavidd functionalmapofsarscov23clproteaserevealstolerantandimmutablesites AT chavezalejandro functionalmapofsarscov23clproteaserevealstolerantandimmutablesites |